Immunovant, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2018 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Immunovant, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2024.
  • Immunovant, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2025 was $18.4M, a 36.8% increase year-over-year.
  • Immunovant, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2025 was $54.4M, a 24.2% increase year-over-year.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $49.5M, a 20.6% increase from 2023.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $41M, a 28.3% increase from 2022.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $32M, a 3.55% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $49.5M +$8.45M +20.6% Apr 1, 2024 Mar 31, 2025 10-K 2025-05-29
2023 $41M +$9.05M +28.3% Apr 1, 2023 Mar 31, 2024 10-K 2025-05-29
2022 $32M -$1.18M -3.55% Apr 1, 2022 Mar 31, 2023 10-K 2025-05-29
2021 $33.1M +$14.5M +77.8% Apr 1, 2021 Mar 31, 2022 10-K 2023-05-22
2020 $18.6M +$11.9M +175% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-08
2019 $6.79M +$6.76M +21797% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-01
2018 $31K Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.